Clinical Research Malaysia (CRM) – Dr. Mohamed Ali Abu Bakar, CEO
Clinical Research Malaysia’s CEO discusses the need for Malaysia to focus on high quality pivotal trials rather than simply on a high number of trials. He shares with us the…
Address: Ministry of Health Lot 36, Jalan Universiti 46350 Petaling Jaya Selangor ,Malaysia
Tel: 03-7841 3200
Web: http://www.pharmacy.gov.my/
The Pharmaceutical Services Division contributes directly to public health by establishing and implementing the national drug registration system besides regulating the pharmaceutical industry through the National Pharmaceutical Control Bureau (NPCB), that assures the quality of medicines in the country.The Division protects consumers from hazardous drugs, misleading medicine advertisements and unscrupulous practices through the enforcement of related drug and pharmacy legislation that control the importation, sale and advertisement of drugs and the practices of pharmacy in the country. The Division provides comprehensive pharmaceutical care by ensuring efficient selection, procurement, distribution of pharmaceuticals; ensuring rational, cost-effective and optimal use of medicines through effective up-to-date clinical and professional pharmaceutical services in tandem with the current global development. The Division consolidates the pharmaceutical sector activities through the implementation of the National Medicines Policy.
The Pharmaceutical Services Division is tasked with the objective of ensuring all pharmaceutical and health products in the market are of quality, safe and efficacious, regulated according to relevant legislations and used rationally. The Division’s core competencies include: Pharmacy Practice, Pharmacy Development, Pharmacy Enforcement and Regulatory Pharmacy.
Clinical Research Malaysia’s CEO discusses the need for Malaysia to focus on high quality pivotal trials rather than simply on a high number of trials. He shares with us the…
The National Heart Institute’s CEO portrays IJN as a national referral center for cardiovascular disease and declares: “IJN is equipped with the best in class technologies and is poised to…
“We believe the future lies with Universal health coverage and the formulation of one and only healthcare, with the merger of public and private sector under one reimbursement system” says…
PEMANDU’s Director for the Healthcare National Key Economic Area gives a thorough understanding of the various entry point projects that were implemented since 2010 to help Malaysia become a high…
Stefan Oschmann, President of the Emerging Markets at Merck and Co. described MSD as the dark horse of the emerging markets. How is MSD performing in Malaysia? Since the merger…
PhAMA was started in 1972 and now has most of the MNC players among its members which include 43 companies. How has the association evolved since its origin and what…
The pharmaceutical industry has been targeted as one of the key growth sectors for the Malaysian economy under the 10th Malaysia Plan, how successful in your opinion have the government…
Without a doubt, Malaysia shares all the major attributes of an emerging market, from the potential to expand market penetration to the increasing purchasing power of the population. So…
2011 marks the 10th anniversary of the company. Over that time you’ve enjoyed notable success including being the first Asian CRO to attain OECD GLP accreditation. Talk us through your…
Since its origin, Emerging Pharma has been helping foreign pharma companies to enter Malaysia. However, the Malaysian market is relatively small. Why should international pharma companies look to this country…
How would you describe the operating environment for foreign companies to use the services of Malaysian companies and how can you reassure these multinationals that sufficient intellectual property protection is…
Malaysia has good ethnic diversity, cost-effective infrastructure, and highly qualified principal investigators (PIs) and these elements have been in place for a long time. Why is now is the right…
See our Cookie Privacy Policy Here
